Pathogenesis
The most common features of pulmonary fibrosis are injury and inflammation, although the extent of involvement or expression may vary depending on the aetiology. The early response to injury in the lung is similar to that in other tissues. Acute inflammation occurs in response to injury of the alveolar epithelium and/or the endothelium of the lung parenchyma, with rapid recruitment and mobilisation of neutrophils to the lung interstitium. In animal models with a single non-persistent insult to the lungs this acute response rapidly subsides and, depending on the magnitude of the injury, is completely replaced by a more chronic mononuclear infiltrate by the end of the first week. 26 In human studies, however, neutrophils may persist, '58 and their role in the subsequent accumulation of connective tissue remains uncertain. Most of the animal model studies suggest a limited or absent role for the neutrophil, while some human studies imply some association with progressive disease and a worse prognosis. Development of therapeutic strategies aimed at controlling neutrophil recruitment and activation should not therefore be ignored and, as will be discussed below, currently available treatment targeted at other aspects offibrogenesis may also have significant effects on the neutrophil response. Although the presence ofeosinophils, basophils, and mast cells has also been described in both human and animal fibrotic specimens, their role in fibrosis has not been established, despite their potential as sources of potentially fibrogenic mediators such as cytokines and eicosanoids.
During the mononuclear phase roles for macrophages/monocytes and lymphocytes have been proposed on the basis that they represent important sources of fibrogenic cytokines such as transforming growth factors a (TGFa) and P (TGF1), tumour necrosis factor a (TNFcI), and eicosanoids such as leukotrienes B4 (LTB4) and C4 (LTC4 The fibrotic response in the lung can be subdivided into relatively distinct stages on factors which affect cellular chemotactic recruitment, activation, proliferation, and extracellular matrix gene expression. However, the events in the various stages are interrelated in terms of common cellular mechanisms and mediators which exert multiple effects on the same or different cells as the fibrosis evolves. Discussion on therapeutic strategies can therefore be subdivided to address these common mechanisms and not the stages of disease progression. As a reflection of the increased understanding at a more basic mechanistic level, the new strategies discussed below will not deal much with older and more generic approaches such as the use ofimmunosuppressive and antiinflammatory agents, but will focus on specific cellular and molecular strategies which may be amenable to control by recently discovered mechanisms (figure). New strategies should also consider even more basic molecular approaches which have been shown to be effective in vitro. They are directed at cytokine expression and include controlling gene expression at the mRNA and perhaps even the DNA level. Control of cytokine expression at the mRNA level by antisense nucleic acid probes has been demonstrated previously.3"36 Success with this approach in vivo depends on the ability to introduce adequate amounts of antisense probe to suppress cytokine production for long enough to arrest fibrosis. In the long term it may be necessary to achieve stable transfection of the antisense probe using vectors. The problem in vivo is therefore the development of an effective delivery method which would be clinically useful. The strategy for treating pulmonary fibrosis is theoretically subject to fewer constraints than that for treatment of genetic diseases where the aim is to correct a more stable long term (if not permanent) impairment ofgene expression. In pulmonary fibrosis there is a sequence of events before the end stage deposition of connective tissue which may be controllable using this antisense approach directed at the inhibition of specific fibrogenic cytokine gene expression. Recent demonstration of relatively stable delivery of nucleic acids via the airway/ endotracheal route37"' supports the feasibility of specifically targeting the lung with the antisense probes, minimising possible untoward systemic effects. This strategy could be extended to any protein whose expression may contribute to the fibrotic process, including the matrix proteins themselves; however, the likelihood for success is reduced with proteins that are highly expressed for more sustained periods of time. The peak production of fibrogenic cytokines (for example, TNFoc and TGF[B) is relatively brief during the pathogenesis of fibrosis, hence they are more susceptible to control by the antisense approach. This strategy could be an improvement on the current use of relatively non-specific immunosuppressive or anti-inflammatory agents.
SIGNAL TRANSDUCTION
An alternative approach is to target the signal transduction apparatus responsible for the regulation of cytokine production. For example, the ability to modulate TNFcz production by eicosanoids40 could be used to control pulmonary fibrosis when this cytokine may be playing a key role in the recruitment and activation of inflammatory cells and fibroblasts. Given the importance of intracellular Ca2+ in signal transduction, calmodulin inhibitors have been tried with some success in the control of experimentally induced pulmonary fibrosis.4' Other approaches will depend on future advances into more unique signal transduction mechanisms for the targeted cytokines, with the advantage ofthe availability ofpharmacological agents which affect cellular signal transduction and the established safety of many of these agents. The disadvantages lie in the relative non-specificity of their effects due to the common sharing ofsignal transduction mechanisms with other cellular processes, and the lack of information on the possible mechanisms of specific relevance to the cytokine(s) of interest.
Thus, the role of these agents as primary treatments for pulmonary fibrosis is likely to be minimal, although their potential usefulness as adjuncts should not be ignored.
ANTIFIBROGENIC CYTOKINES
The enhancement of the production of antifibrogenic cytokines such as interferon-y (IFNy)'4243 has been shown to be beneficial in animal model studies using poly I:C as interferon inducer44 and confirmed by the direct administration of IFNy itself.4""7 Other potentially useful antifibrogenic cytokines have the ability to inhibit inflammatory/immune cell activation, and these paradoxically include TGFI. Recent studies indicate the importance of TGF3 as an endogenous downregulator of inflammation.4849 This approach is likely to be limited by the wide range of bioactivity of these cytokines which makes them too non-specific to be therapeutically useful.
Inflammation and tissue injury
The contribution of inflammation to tissue injury was the basis for the early use of antiinflammatory agents (steroids, alkylating agents and non-steroidal anti-inflammatory preparations) in treating pulmonary fibrosis but with little success.'2 Other data suggest that cyclooxygenase inhibitors could exacerbate fibrosis by abrogating inhibition of collagen synthesis and cytokine production by endogenous prostaglandins.0 In contrast, the stimulatory potential of lipoxygenase pathway products, such as leukotrienes, on cytokine and collagen production5"53 argue for the use of lipoxygenase inhibitors and leukotriene antagonists in the treatment of pulmonary fibrosis. Many such agents have been developed recently, directed primarily at the treatment of asthma, and it is a matter now of testing their efficacy in fibrotic diseases. Recent work on the mechanism of lipoxygenase activation5455 has opened up research into pharmacological agents for controlling leukotriene production. The role of steroids in the future is likely to remain limited in view of their side effects and relative lack of specificity and efficacy.
ANTIOXIDANTS
Despite early recruitment of phagocytes in many forms of lung injury and fibrosis, there is only limited support for the role of neutrophils, oxidants, and proteases in the pathogenesis of pulmonary fibrosis.'1256 However, an approach to control inflammation-associated injury should be directed primarily at the production and effects of oxidants and proteases released by activated phagocytes, and perhaps even the target cells themselves.5657 In addition to direct injurious effects, oxidants may also upregulate cytokine production, possibly via activation of NF-KB58 which may indirectly promote fibrosis. Several antioxidants and inhibitors of phagocyte activation have been evaluated for possible inhibition ofpulmonary fibrosis in animal models2 but the results of these studies are con-flicting. Superoxide dismutase, catalase, and desferrioxamine have been found to ameliorate asbestosis-associated pulmonary disease, while the effects are equivocal in bleomycin-induced injury."'-" N-acetyl cysteine and combinations of taurine and niacin have been used to control the latter,63-65 although whether the effects are mediated by the control of oxidant-mediated tissue injury remains undetermined. More recently, with the discovery of nitrogen-centred radicals as possible mediators of tissue injury, inhibitors of nitric oxide synthetase have been investigated for control of pulmonary fibrosis; however, the evidence is still too preliminary for any therapeutic strategy. A potential drawback is that these inhibitors may inhibit the endogenous production of nitric oxide necessary for vasodilatation which may be an important beneficial physiological response to injury.
ANTIPROTEASES
Experience with antiproteases has been limited, despite evidence that proteolytic activity in bronchoalveolar lavage fluid may be associated with progressive disease and a poor prognosis.12566 ox1-Antiprotease is effective in ameliorating pulmonary fibrosis in a model67 but needs wider testing to evaluate its clinical potential. Protease inhibitors may have an indirect effect by controlling oxidant production, possibly at the level of mediation of the activation of phagocytes and/or endothelial cell xanthine oxidase by signal transduction. 57 The use of non-proteinaceous inhibitors and antioxidants such as vitamin E, N-acetylcysteine, and iron chelators (for example, desferrioxamine) is preferable from a pharmacological standpoint, as they are easier to administer than the proteinaceous agents. Future advances will depend on the discovery of more specific, potent but less toxic antioxidants, assuming that the culprit oxidants can be identified.
INHIBITION OF CELL ADHESION
The possibility that inflammation and its undesirable sequelae could be prevented by blocking inflammatory cell adhesion is suggested by recent studies using antibodies to selected cell adhesion molecules.8 Direct evidence that pulmonary fibrosis can be controlled by such an approach is provided by the ability of anti-CD1 1 antibodies to inhibit collagen deposition in animal models induced by bleomycin or silica.68 The mechanism of fibrosis inhibition is not understood, but the reduction in alveolitis, lymphoid infiltrate, and platelet microthrombi suggest that generalised inhibition of intercellular adhesion may contribute to the effect. Since there is extensive and generally positive experience with monoclonal antibodies in clinical practice, the use of monoclonal antiadhesion molecule antibodies to control pulmonary fibrosis may represent a future development.
These strategies may not be generally applicable throughout the spectrum ofpulmonary fibrosis, as tissue injury by oxidants and proteases may not be a key component of fibrosis and, at the time of clinical detection, the tissue injury process may be far advanced or irreversible. However, where investigations suggest that the disease is at an early stage with an important oxidant component, these approaches may be effective. Other treatments directed at other facets of the fibrotic process may also have an impact on oxidant and/or protease mediated injury. These are discussed in the relevant sections.
Little information is available on the role(s) (if any) of the humoral aspects of inflammation and platelets in pulmonary fibrosis. Evidence suggests an insignificant role for platelets,2 and few studies have addressed the issue of kinins or the coagulation pathway. Serum complement appears to be important in animal models of fibrosis, but the mechanistic basis for its role has not been defined.69
Immune response The immune response is important in the pathogenesis of many forms of pulmonary fibrosis.`7 Although the expected role of the immune system in autoimmune and other immunologically-mediated diseases in sustaining fibrosis-associated inflammation is well known, the cell-mediated immune mechanisms responsible for lung fibrosis, and the offending antigen(s) inciting the immune response, are unknown in many forms of the disease. Both clinically and in animal models there is good evidence of a role for the immune system, despite the inability to identify a specific antigen. Cell-mediated immunity to type I collagen has been reported in some cases of idiopathic pulmonary fibrosis and in an animal model2 but the importance of this response to the pathogenesis of fibrosis is unclear. Nevertheless, early treatments have primarily relied on suppressing the immune system with steroids and other immunosuppressive agents, and they are more effective where the immune response is an important aetiological factor.2 7072 The drawbacks, in addition to lack of efficacy in many forms of the disease, include the possibility that some of the immunosuppressive agents themselves may be fibrogenic.2
Given the important role of the immune system, however, immunosuppression with fewer side effects should be an important part of any future strategy. Recent studies using cyclosporin A in both man and animal models have yielded promising results.73-7 Even more selective immunosuppression can be envisaged by suppression of T cell subpopulations, with cytotoxic cell type specific antibodies or desensitisation to an offending antigen. These approaches have been used successfully in other diseases, and the increasing ability to manufacture monoclonal antibodies makes this an attractive approach for controlling pulmonary fibrosis. The advantage of using these agents is their greater specificity compared with steroids and other general immunosuppressive agents.
As with the anti-inflammatory agents, it is unlikely that immunosuppression alone would adequately treat the whole spectrum of pulmonary fibrosis. Additional and possibly synergistic effects may be obtained by targeting the immune response at the regulatory cytokine, eicosanoid, or signal transduction levels, using the approaches described above for cytokine imbalance. Even where a specific antigen has not been identified, the approaches described in this section may be partially effective.
Extracellular matrix deposition
The ultimate effect of pulmonary fibrosis is the replacement of normal lung parenchyma by connective tissue. Although this matrix is complex, more data are available on the accumulation of collagen than other matrix components. Ideally, a selective method could be developed in which abnormal deposition of lung collagen is controlled to allow for normal repair to take place. It offers the possibility that patients could be treated during the later stages of the disease, but success will depend on the ability to inhibit matrix production selectivity to allow normal repair to continue. Treatment will be limited to a short time only so that collagen synthesis in other organs is not impaired. Animal model studies suggest that an early event characterised by inflammation and increased cytokine production precedes the period of increased collagen gene expression,2 3 5-7 suggesting a cause and effect relationship between these two sequential stages. The control of collagen synthesis by itself may not therefore be sufficient to control progressive fibrosis if the increase in cytokine production driving the upregulation in collagen production persists beyond the period of therapeutic efficacy of the collagen synthesis inhibitors. It is likely that successful treatment will require that the cause for the increase in collagen deposition (for example, cytokine production) should also be controlled.
PROLINE ANALOGUES
Despite these theoretical limitations, there has been some success with using inhibitors of collagen deposition in animal models. A number of proline analogues have been tried in animal models -including fibrosis in organs other than lung -with variable success and toxicity.2 However, toxicity associated with generalised inhibition of collagen production in non-targeted tissues makes this approach much less attractive. This problem can be partially prevented by using tissue-specific inhibitors, such as the one developed for selective inhibition of liver collagen synthesis based on synthesising inactive esters of the inhibitor (pyridine 2,4-dicarboxylate) which are activated only in the liver.78 In the lung this would depend on the identification of lung-specific enzymes with analogous properties.
PROCOLLAGEN TERMINAL PROPEPTIDES
Another approach to controlling collagen synthesis is to exploit the negative feedback properties of procollagen terminal propeptides. 79 81 Synthetic analogues may be developed with similar properties for therapeutic purposes."" However, levels of these peptide fragments are already raised in the plasma of individuals with active fibrotic processes,82 83 and fibroblasts isolated from fibrotic tissue may be more resistant to negative feedback control by such peptides.84
Not all propeptides behave similarly in regulating collagen synthesis, however, some being inhibitory and others stimulatory.81 If a select group of peptides can be identified with potent inhibitory properties, this approach may therefore be feasible where collagen synthesis needs to be controlled for a brief period, where the fibrosis-inducing stimulus is temporary, or can be controlled by removing an offending agent.
POST-TRANSLATIONAL CONTROL
Another method is to control collagen crosslinking using agents such as penicillamine and lathyrogens, such as 3-aminopropionitrile.2 An additional aim is to disrupt the secretory process in extracellular collagen deposition which relies on disruption of the cytoskeletal machinery. Although these studies show some success, toxic effects are common. Thus, approaches to inhibit collagen synthesis directly at the post-translational level are unlikely to produce results.
ANTISENSE APPROACH AND OTHER INHIBITORS
With increasing understanding ofthe regulation of collagen gene expression, new approaches using antisense probes directed at the specific collagen mRNA of interest may be feasible, as discussed above for cytokines. Known inhibitors of collagen production whose efficacy has already been tested in animal models include IFNy and prostaglandin E2 (PGE2) which inhibit collagen synthesis and stimulate its degradation,2 and IFNy also inhibits bleomycininduced pulmonary fibrosis.43A7 There is also evidence that stable synthetic PGE2 analogues may be effective in reducing fibrosis.85 The mechanism for these two agents, however, is unlikely to be mediated solely via the inhibition of collagen production, and may also affect other aspects of the fibrotic process. Some of these reagents are available and have been approved for clinical use in other disorders.
Miscellaneous
Other agents have been found to be effective in controlling pulmonary fibrosis in animal studies but their mechanisms remain uncertain, making them difficult to classify. The efficacy of niacin and taurine has been mentioned above as a possible antioxidant mechanism. More curious is the efficacy of the angiotensin converting enzyme (ACE) inhibitor8687 and, given the extensive clinical experience with this class of drugs, more should be done to pursue an understanding of the mechanism underlying its potential therapeutic value. Significant toxicity ofpenicillamine and colchicine has limited their usefulness, but this is combined with equivocal therapeutic efficacy. 
